company background image
1875 logo

TOT BIOPHARM International SEHK:1875 Stock Report

Last Price

HK$1.62

Market Cap

HK$1.3b

7D

-7.4%

1Y

-23.9%

Updated

19 Dec, 2024

Data

Company Financials +

TOT BIOPHARM International Company Limited

SEHK:1875 Stock Report

Market Cap: HK$1.3b

1875 Stock Overview

An investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. More details

1875 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance2/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 20.53% per year

Became profitable this year

Risk Analysis

Large one-off items impacting financial results


My Notes

Capture your thoughts, links and company narrative

TOT BIOPHARM International Company Limited Competitors

HBM Holdings

SEHK:2142

HK$893.6m

Essex Bio-Technology

SEHK:1061

HK$1.6b

Uni-Bio Science Group

SEHK:690

HK$382.2m

Shanghai Henlius Biotech

SEHK:2696

HK$13.0b

Price History & Performance

Summary of share price highs, lows and changes for TOT BIOPHARM International
Historical stock prices
Current Share PriceHK$1.62
52 Week HighHK$2.79
52 Week LowHK$1.48
Beta0.23
1 Month Change-14.29%
3 Month Change-19.00%
1 Year Change-23.94%
3 Year Change-58.99%
5 Year Change-64.00%
Change since IPO-74.12%

Recent News & Updates

TOT BIOPHARM International Company Limited's (HKG:1875) Low P/S No Reason For Excitement

Dec 18
TOT BIOPHARM International Company Limited's (HKG:1875) Low P/S No Reason For Excitement

We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Jun 07
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Recent updates

TOT BIOPHARM International Company Limited's (HKG:1875) Low P/S No Reason For Excitement

Dec 18
TOT BIOPHARM International Company Limited's (HKG:1875) Low P/S No Reason For Excitement

We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

Jun 07
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation

The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More

May 21
The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More

Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

Mar 18
Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?

There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues

Dec 28
There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues

Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

Nov 23
Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?

We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

May 18
We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Jul 27
Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued

Mar 26
An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued

Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Feb 03
Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation

Shareholder Returns

1875HK BiotechsHK Market
7D-7.4%-3.6%-0.9%
1Y-23.9%-4.5%19.2%

Return vs Industry: 1875 underperformed the Hong Kong Biotechs industry which returned -4.5% over the past year.

Return vs Market: 1875 underperformed the Hong Kong Market which returned 19.2% over the past year.

Price Volatility

Is 1875's price volatile compared to industry and market?
1875 volatility
1875 Average Weekly Movement7.9%
Biotechs Industry Average Movement11.0%
Market Average Movement8.9%
10% most volatile stocks in HK Market18.7%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 1875 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1875's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009572Jun Liuwww.totbiopharm.com

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops and markets Pusintin, a bevacizumab injection for the treatment of non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; cervical cancer; and hepatocellular carcinoma. It also offers Tazian, a temozolomide capsule for the treatment of glioblastoma multiforme or anaplastic astrocytoma; and Megaxia, a megestrol acetate oral suspension for the treatment of anorexia associated with acquired immunode¬ciency syndrome, as well as signi¬cant weight loss of AIDS and cancer patients caused by cachexia.

TOT BIOPHARM International Company Limited Fundamentals Summary

How do TOT BIOPHARM International's earnings and revenue compare to its market cap?
1875 fundamental statistics
Market capHK$1.28b
Earnings (TTM)HK$9.55m
Revenue (TTM)HK$1.04b

131.1x

P/E Ratio

1.2x

P/S Ratio

Is 1875 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1875 income statement (TTM)
RevenueCN¥973.17m
Cost of RevenueCN¥272.28m
Gross ProfitCN¥700.89m
Other ExpensesCN¥691.93m
EarningsCN¥8.97m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.012
Gross Margin72.02%
Net Profit Margin0.92%
Debt/Equity Ratio52.9%

How did 1875 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 09:48
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TOT BIOPHARM International Company Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xin Qiu LinGuoyuan Securities (HK) Ltd
Yue-Kwong LuiJefferies LLC